Department of Dermatology, Mater Adult Hospital, South Brisbane, Queensland, Australia.
J Eur Acad Dermatol Venereol. 2013 Sep;27(9):1109-13. doi: 10.1111/j.1468-3083.2012.04669.x. Epub 2012 Aug 22.
Quality of life (QOL) issues in patients with non-metastatic skin cancer are not satisfactorily demonstrated when using existing QOL questionnaires.
To construct and validate a 10 item disease-specific QOL questionnaire, the Skin Cancer Quality of Life Impact Tool (SCQOLIT), for use in patients following treatment of non-metastatic skin cancer.
The SCQOLIT was constructed and administered initially to 120 patients with non-metastatic skin cancer, 60 with malignant melanoma (MM) and 60 with non-melanoma skin cancer (NMSC) following treatment, then repeated in half this cohort at seven days, and the other half at three months. Data was collected on age, gender, skin cancer type and Breslow thickness. Statistical validation was undertaken.
There were 113 valid SCQOLIT responses at initial completion (54 in the MM group, and 59 in the NMSC group). Initial SCQOLIT median scores (interquartile range [IQR], range) for the two groups were 10 (12, 0-28) MM, and 4 (5, 0-19) NMSC. Amongst the cohort readministered the SCQOLIT at three months (23 in the MM group, 25 in the NMSC group) median scores (IQR, range) were 6 (6, 0-26) MM and 3 (4, 0-20) NMSC.
The SCQOLIT is a validated disease-specific QOL questionnaire for use in patients following treatment of non-metastatic skin cancer. Higher SCQOLIT scores are observed in MM patients than NMSC patients, but diminish with time in the MM group. Patients with persistently elevated SCQOLIT scores merit additional attention.
在使用现有的生活质量问卷时，非转移性皮肤癌患者的生活质量问题无法得到满意的体现。
构建和验证一种 10 项疾病特异性生活质量问卷，即皮肤癌生活质量影响工具（SCQOLIT），用于治疗非转移性皮肤癌后的患者。
SCQOLIT 最初在 120 名非转移性皮肤癌患者中进行构建和管理，其中 60 名患有恶性黑色素瘤（MM），60 名患有非黑色素瘤皮肤癌（NMSC），然后在这一半队列的 7 天和另一半的 3 个月进行重复。收集年龄、性别、皮肤癌类型和 Breslow 厚度的数据。进行了统计验证。
初始完成时，有 113 份有效的 SCQOLIT 回复（MM 组 54 份，NMSC 组 59 份）。两组的初始 SCQOLIT 中位数评分（四分位距 [IQR]，范围）分别为 MM 组 10（12，0-28），NMSC 组 4（5，0-19）。在三个月重新管理 SCQOLIT 的队列中（MM 组 23 名，NMSC 组 25 名），中位数评分（IQR，范围）分别为 MM 组 6（6，0-26）和 NMSC 组 3（4，0-20）。
SCQOLIT 是一种经过验证的、用于治疗非转移性皮肤癌后患者的疾病特异性生活质量问卷。MM 患者的 SCQOLIT 评分高于 NMSC 患者，但在 MM 组中随时间下降。持续存在高 SCQOLIT 评分的患者需要额外关注。
